每经记者｜徐肖逍 每经编辑｜杨夏 日前，美国减肥药巨头礼来（US LLY）宣布，其GIP/GLP-1药物穆峰达（注：替尔泊肽注射液）获得中国国家药品监督管理局（NMPA）批准，成为首个且 目前唯一用于治疗成人肥胖患者的中度至重度阻塞性睡眠呼吸暂停（OSA）的处方药。 随着GLP-1减肥药赛道竞争日趋激烈，企业间的比拼正从单一的减重疗效，逐步延伸至睡眠呼吸暂停等肥胖相关的并发症上。 Wind数据显示，A股减肥药概念共包含24家企业。每经品牌价值研究院统计发现，其中15家已经发布2024年度ESG相关报告，披露率为62.5%，高于A股46% 的平均水平。同时，每日经济新闻与中央财经大学绿色金融国际研究院（以下简称中财大绿金院）合作开发的"ESG行动派"数据平台显示，A股减肥药概念 股中45.8%的ESG评级处于A级（含A+、A及A-），研发投入头尾部差距较大。 中财大绿金院ESG中心联合主任包婕在接受《每日经济新闻》记者采访时表示，通过ESG评级结果可以发现，在公司治理方面存在风险的企业，往往整体非 财务表现也不佳，有缺陷的公司治理模式导致企业无法在其他维度做到规范。她建议，这类企业需完善内部公司治理架构、机制、 ...

此外，就在7月1日，翰宇药业发布今年半年利润的业绩预告称：2025年上半年，公司预计实现归母净利 润1.42亿-1.62亿元，同比增幅高达1470%-1664%；扣非净利润1.22亿元-1.42亿元，同比增长 304.27%-337.76%。值得注意的是，翰宇药业能做到这一步实在不容易，公司曾陷于扣非净利润亏损长 达7年之久，这还是首次实现扭亏为盈。翰宇药业将最大功臣归于其"减重神药"利拉鲁肽注射液仿制药 的出海成功以及原料药的国际收入和成本控制等。去年12月，其仿制的利拉鲁肽注射液在美国上市，并 和美国合作伙伴Hikma采取"低出货价+高利润分成的BD"模式。 外资药企进军新赛道 与此同时，外资药企也并没有"坐等"后来者赶超，而是在不断开拓进军新赛道。就在2025年6月30日， 礼来宣布穆峰达®（替尔泊肽注射液）获得中国国家药品监督管理局批准，成为首个且目前唯一用于治 疗成人肥胖患者的中度至重度阻塞性睡眠呼吸暂停（OSA）的处方药。替尔泊肽可改善中度至重度阻塞 性睡眠呼吸暂停肥胖成人患者的睡眠障碍。该适应症的使用需在控制饮食和增加运动基础上进行。 据悉，除了改善睡眠呼吸暂停症状外，接受替尔泊肽治疗的成人患者 ...

7月3日，迪哲医药公告称，舒沃哲（通用名：舒沃替尼片）的新药上市申请，正式获得美国食品药品监 督管理局（FDA）批准，用于既往经含铂化疗治疗时或治疗后出现疾病进展，并且经FDA批准的试剂盒 检测确认，存在表皮生长因子受体（EGFR）20号外显子插入突变（exon20ins）的局部晚期或转移性非 小细胞肺癌（NSCLC）的成人患者。 点评：舒沃哲是中国首个独立研发、在美获批的全球首创新药，此次获批有望提升迪哲医药在国际市场 的声誉，也为国产创新药出海提供了新的示范案例。 NO.3 先声药业恩泽舒获批上市，为中国首个铂耐药卵巢癌全人群适用靶向药 7月3日，先声药业旗下创新药子公司先声再明宣布，其在中国开发的新一代抗肿瘤血管生成（抗VEGF 抗体）一类生物新药恩泽舒（通用名：注射用苏维西塔单抗）已正式获中国国家药品监督管理局批准上 市。恩泽舒获批适应证为联合紫杉醇、多柔比星脂质体或拓扑替康用于铂耐药后接受过不超过1种系统 治疗的成人复发性卵巢癌、输卵管癌或原发性腹膜癌的治疗。 每经记者｜许立波 每经编辑｜张益铭 丨2025年7月4日 星期五丨 NO.1 礼来替尔泊肽获批第三项适应证 7月3日，礼来宣布，其GIP/G ...

③ 【猫途鹰盘前涨超5%】全球旅游网站猫途鹰（TripAdvisor Inc.）盘前涨超5%。消息面上，据外媒， Starboard Value LP对该公司持股超过9%。 ④ 【Datadog将被纳入标普500指数，盘前涨超11%】服务器、数据库等的监控服务商Datadog盘前涨超 11%。消息面上，据标普道琼斯指数公司，Datadog将被纳入标普500指数。 ① 【三大期指齐涨】截至发稿，道指期货涨0.05%、标普500指数期货涨0.07%、纳指期货涨0.11%。 ② 【芯片设计软件股盘前走高】芯片设计软件股盘前走高，新思科技、楷登电子均涨超6%。 ⑤ 【礼来替尔泊肽获批第三项适应症】据礼来消息，其GIP/GLP-1药物替尔泊肽注射液获得中国国家药 品监督管理局（NMPA）批准，成为首个且目前唯一用于治疗成人肥胖患者的中度至重度阻塞性睡眠呼 吸暂停（OSA）的处方药。这也是该产品获批的第三项适应症。此前，NMPA批准了替尔泊肽用于治疗 2型糖尿病和长期体重管理两项适应症。 ⑨ 北京时间20:30，美国6月非农就业人口变动发布。 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前核实。据此操作，风险自 ...

Core Insights - Eli Lilly's drug Mounjaro (tirzepatide) has received approval from China's National Medical Products Administration (NMPA) for a new indication to treat moderate to severe obstructive sleep apnea (OSA) in obese adults, marking it as the first and only prescription medication for this condition in China [1] - The approval is based on the results of the SURMOUNT-OSA Phase 3 clinical trial, which evaluated the drug's effectiveness in obese adults with OSA who were either receiving or unwilling to receive positive airway pressure (PAP) therapy [1] Group 1: Clinical Trial Results - Tirzepatide reduced the number of apnea-hypopnea events by five times compared to placebo in adults not using PAP, with a reduction of 27 events per hour versus 5 for placebo [2] - In adults using PAP, tirzepatide led to a reduction of 30 events per hour compared to 6 for placebo [2] - After one year of treatment, 43% of patients using tirzepatide alone achieved complete resolution of OSA symptoms or a mild OSA state, while 52% of those using both tirzepatide and PAP achieved similar results; the placebo group had rates of 15% and 14% respectively [2] Group 2: Weight Loss and Safety - Patients treated with tirzepatide alone experienced an average weight loss of 18.1%, while those receiving both tirzepatide and PAP lost an average of 20.1%; the placebo group saw weight losses of 1.3% and 2.3% respectively [2] - The safety and tolerability profile of tirzepatide remained consistent with previous trials, with gastrointestinal adverse events being the most common, typically mild to moderate in severity [2]

近一年以来，国家药监局已经批准了替尔泊肽用于治疗2型糖尿病和长期体重管理两项适应症。这项最 新获批的OSA适应症的使用，需在控制饮食和增加运动基础上进行。 接受替尔泊肽治疗的成人患者平均减重20%，睡眠中每小时呼吸暂停低通气次数至少减少27次。在接受 替尔泊肽治疗一年后，半数以上患者已不再有OSA相关症状。 7月3日，礼来宣布GLP-1类减重药替尔泊肽注射液（商品名：穆峰达）已获得中国国家药品监督管理局 （NMPA）批准，用于治疗成人肥胖患者的中度至重度阻塞性睡眠呼吸暂停（OSA）。该药物也是全球 首个且目前唯一用于治疗OSA的处方药。 OSA还与各种不良心血管疾病事件（CVD）的发生密切相关。去年发布的一份《心血管疾病患者阻塞 性呼吸睡眠暂停评估与管理专家共识（2024 版）》为我国CVD患者中OSA的评估和管理提供规范性指 导。 然而，由于患者对OSA疾病严重性认识不足，目前患者就诊率偏低，面临着严重的健康风险。 去年12月，美国FDA已经批准了替尔泊肽OSA适应症。随着该适应症在全球更多国家获批，将使礼来在 激烈的减重药市场竞争中更具优势。 礼来临床数据显示，接受替尔泊肽治疗的成人患者平均减重20%，睡 ...

礼来宣布穆峰达(替尔泊肽注射液)获得中国国家药品监督管理局(NMPA)批准，成为首个且目前唯一用 于治疗成人肥胖患者的中度至重度阻塞性睡眠呼吸暂停(OSA)的处方药。替尔泊肽可改善中度至重度阻 塞性睡眠呼吸暂停肥胖成人患者的睡眠障碍。该适应症的使用需在控制饮食和增加运动基础上进行。 (21世纪经济报道) ...

Core Insights - Hanyu Pharmaceutical (300199) has recently conducted investor research, discussing the progress of the HY3003 new drug project, its layout in the innovative drug field, and overseas market expansion [1][2] Group 1: HY3003 New Drug Project - The HY3003 project has completed preclinical candidate compound screening and raw material process development, officially entering the raw material pilot scale-up phase, which validates the producibility of the molecular structure for subsequent IND application and clinical transformation [1] - HY3003 is a GLP-1R/GIPR/GCGR receptor agonist developed using AI peptide chip technology, aimed at weight loss indications [1] - The project employs a multi-formulation parallel development strategy, including weekly, ultra-long-acting monthly, and oral formulations, with the ultra-long-acting formulation designed to reduce dosing frequency and improve medication adherence [1] Group 2: siRNA and Other Drug Developments - The company is also developing siRNA drugs such as Inclisiran and Zilebesiran for treating high cholesterol and hypertension, as well as Pegcetacoplan for treating geographic atrophy [1] Group 3: Overseas Market Expansion - Currently, the company's raw materials are sold to over 20 countries and regions, with formulations licensed in over 90 countries and regions [2] - The company has signed cooperation agreements for the semaglutide injection (weekly formulation) and oral tablets in markets including China, Brazil, Egypt, Mexico, Eurasian Union, GCC member countries, and North Africa [2] - The company has completed the enrollment of all participants in the Phase III clinical trial for semaglutide injection as of January this year, with plans to submit for approval in China by 2026, followed by the US and other global markets [2] Group 4: Future Pipeline - Hanyu Pharmaceutical has a rich pipeline of peptide and small nucleic acid formulations, planning to launch no less than 20 formulations over the next 10 years, including innovative drugs, micro-innovative drugs, and ANDA [2]

礼来宣布替尔泊肽注射液多剂量预装笔在中国正式上市 金十数据6月13日讯，礼来宣布穆峰达®（替尔泊肽注射液多剂量预装笔）在中国正式上市。替尔泊肽 注射液多剂量预装笔覆盖适应症为在饮食控制和运动基础上，接受二甲双胍和/或磺脲类药物治疗血糖 仍控制不佳的成人2型糖尿病（简称：T2DM）患者。据介绍，穆峰达（替尔泊肽注射液）是全球首个 且目前唯一获批用于T2DM和长期体重管理的每周一次葡萄糖依赖性促胰岛素多肽（GIP）/胰高糖素样 肽-1（GLP-1）受体激动剂。 （36氪） ...

Policy Developments - The National Health Commission of China is taking measures to ensure blood supply in key areas and important time periods due to a noticeable decline in voluntary blood donations, influenced by factors such as aging population and lifestyle changes [2] - In 2024, the total blood supply in China is expected to decrease year-on-year, with a cumulative blood allocation of 3.613 million units, including 583,000 units allocated between provinces, representing a 35.1% increase [2] Drug and Medical Device Approvals - Kelun Pharmaceutical announced that its subsidiary has received drug registration approval for "Cefazolin Sodium/ Sodium Chloride Injection," which is packaged in a dual-chamber bag and is suitable for emergency treatment [4] - *ST Sailong's subsidiary has obtained a drug registration certificate for Famotidine Injection, classified as a Category A drug under the national medical insurance list, primarily used for treating upper gastrointestinal bleeding [5] Capital Market Activities - Borui Pharmaceutical plans to invest 20 million yuan to subscribe to the increased registered capital of Geek Gene Technology, acquiring a 4.1667% stake in the company [7] Industry Developments - Eli Lilly announced the launch of the multi-dose prefilled pen for Tirzepatide Injection in China, aimed at addressing the needs of the growing number of diabetes and obesity patients [9] - The adult overweight rate in China is 34.3%, with an obesity rate of 16.4%, highlighting the increasing demand for weight management treatments [9] - In the first quarter of this year, Tirzepatide contributed $6.15 billion in revenue to Eli Lilly, accounting for approximately 48% of the company's total revenue [10] - Hanyu Pharmaceutical has completed the enrollment of all subjects for the Phase III clinical trial of Semaglutide Injection for weight management, currently in the follow-up phase [11] Shareholder Actions - Nine Strong Bio's major shareholder completed a share reduction plan, reducing their holdings from 30,969,636 shares to 30,769,636 shares, a decrease from 5.30% to 5.26% of voting shares [13] - Yifeng Pharmacy's controlling shareholder plans to reduce their stake by up to 2%, amounting to no more than 24,248,336 shares [14]